S. 1041Introduced
Affordable Prescriptions for Patients Act
Plain-English overview
What this bill does
Limits certain patent assertions in biologic drug litigation to streamline biosimilar challenges under the FDA approval framework
Key points
- Limit patent assertions
- Allow increased patent limits
- Exclude certain method patents
Current status
Where it stands
Status
Introduced
Latest action
2026-07-21 — Held at the desk.
Related context
Topics and policy areas
Select a topic to continue exploring related legislation, members, and committees.
Discovery signals
About these signals
Impact and Momentum are relative discovery aids calculated by Legislation Lemur. They help you scan the congressional record; they are not predictions, endorsements, ideological ratings, or measures of policy importance.
Impact ScoreOverall observed legislative footprint and accumulated activity.
MomentumHow recently active or changing the bill appears in available data.